SEC Form 4	
------------	--

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burg	den
hours per response:	0.5

Trust dated March 13, 2002

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

				01 00		nooune		mpany not on	10.10						
1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol Atea Pharmaceuticals, Inc. [AVIR]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
<u>Murphy Polly A.</u>									2	Director	10%	Owner			
(Last) 125 SUMME	(First) R STREET	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 11/03/2020									other (specify elow)		
					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable				
(Street)											Line)				
BOSTON	MA	02110									X Form filed by One Reporting Person				
p											Form filed by More than One Reporting Person				
(City)	(State)	(Zip)													
		Table I - No	on-Deriva	tive S	Securities Acq	uired	, Dis	posed of,	or Ber	neficially	y Owned				
1. Title of Security (Instr. 3) Date (Month/Date)				Execution Date,				4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
													Held by		
													the Marc		
													& Polly		
													Murphy		
Common Stock 11/03/2				020		с		11,295	A	(1)	11,295	I	Revocable		
					1				1		,00	1	Family		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series D Convertible Preferred Stock	(1)	11/03/2020		С			7,122	(1)	(1)	Common Stock	7,122	(1)	0	I	Held by the Marc & Polly Murphy Revocable Family Trust dated March 13, 2002
Series D-1 Convertible Preferred Stock	(1)	11/03/2020		С			4,173	(1)	(1)	Common Stock	4,173	(1)	0	I	Held by the Marc & Polly Murphy Revocable Family Trust dated March 13, 2002

Explanation of Responses:

1. The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

Remarks:

/s/ Andrea Corcoran, attorney-11/03/2020

in-fact for Polly A. Murphy

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.